Official Title
Serological and Functional Impact of COVID-19 Vaccination on the Maternal Fetal Unit and Infant Immunity
Brief Summary

This is a prospective longitudinal cohort study to evaluate the impact of COVID-19vaccination and booster on maternal and infant immunity against COVID-19 variants overtime.

Detailed Description

We will enroll 100 pregnant patients who have received COVID-19 mRNA booster as well as
100 breastfeeding patients who have received COVID-19 mRNA booster. Participants will be
following longitudinally through 3 months post partum, or 3 months post enrollment for
those in the breastfeeding cohort. Maternal blood will be collected, as will cordblood at
delivery, breastmilk, and infant samples.

Status
Recruiting
Conditions
COVID-19
Interventions

Drug: Bivalent COVID-19 Booster

Bivalent COVID-19 Booster by Pfizer or Moderna

Eligibility Criteria

Inclusion Criteria:

- Singleton gestation

- Received mRNA bivalent COVID-19 booster during 1) pregnancy or 2) breastfeeding

Exclusion Criteria:

- Multifetal gestation

- Unable to provide consent

Eligibility Gender
Female
Eligibility Age
Minimum: 13 Years ~ Maximum: 55 Years
Countries
United States
Locations

Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States

Investigator: Rupsa C Boelig, MD
rupsa.boelig@jefferson.edu

Contacts

Brandy Firman
215-586-1656
brandy.firman@jefferson.edu

Rupsa Boelig
215-955-9196
rupsa.boelig@jefferson.edu

Investigators

Rupsa C Boelig, MD, Principal Investigator
Thomas Jefferson University

Sponsors / Collaborators
Thomas Jefferson University
NCT Number
NCT05543993
Keywords
Vaccine
COVID-19 vaccine
Booster
pregnancy
breastfeeding
Immunity
MeSH Terms
COVID-19